Eli Lilly and Co. reported mid-stage trial data showing that individuals with mild to moderate Alzheimer's disease who took its monoclonal antibody drug donanemab had 32% slower cognitive decline rate compared with those who were given placebo. Donanemab treatment also correlated with removal and persistent absence of amyloid plaques after six to 12 months, according to Eli Lilly Chief Scientific Officer Dr. Daniel Skovronsky.
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.